153 related articles for article (PubMed ID: 2783301)
1. An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys.
Hertler AA; Schlossman DM; Borowitz MJ; Poplack DG; Frankel AE
Cancer Immunol Immunother; 1989; 28(1):59-66. PubMed ID: 2783301
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and toxicology of immunotoxins administered into the subarachnoid space in nonhuman primates and rodents.
Muraszko K; Sung C; Walbridge S; Greenfield L; Dedrick RL; Oldfield EH; Youle RJ
Cancer Res; 1993 Aug; 53(16):3752-7. PubMed ID: 8339287
[TBL] [Abstract][Full Text] [Related]
3. Autologous transplantation of bone marrow purged in vitro with anti-CD7-(WT1-) ricin A immunotoxin in T-cell lymphoblastic leukemia and lymphoma.
Preijers FW; De Witte T; Wessels JM; De Gast GC; Van Leeuwen E; Capel PJ; Haanen C
Blood; 1989 Aug; 74(3):1152-8. PubMed ID: 2473811
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic potential of anti-CD7 immunotoxin (WT1-ricin A) to purge ex vivo malignant T cells in bone marrow.
Preijers FW; De Witte T; Wessels JM; Meyerink JP; Haanen C; Capel PJ
Br J Haematol; 1989 Feb; 71(2):195-201. PubMed ID: 2784323
[TBL] [Abstract][Full Text] [Related]
5. Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin.
Frankel AE; Laver JH; Willingham MC; Burns LJ; Kersey JH; Vallera DA
Leuk Lymphoma; 1997 Jul; 26(3-4):287-98. PubMed ID: 9322891
[TBL] [Abstract][Full Text] [Related]
6. Intraventricular immunotoxin therapy for leptomeningeal neoplasia.
Laske DW; Muraszko KM; Oldfield EH; DeVroom HL; Sung C; Dedrick RL; Simon TR; Colandrea J; Copeland C; Katz D; Greenfield L; Groves ES; Houston LL; Youle RJ
Neurosurgery; 1997 Nov; 41(5):1039-49; discussion 1049-51. PubMed ID: 9361057
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
[TBL] [Abstract][Full Text] [Related]
8. Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin.
Wawrzynczak EJ; Watson GJ; Cumber AJ; Henry RV; Parnell GD; Rieber EP; Thorpe PE
Cancer Immunol Immunother; 1991; 32(5):289-95. PubMed ID: 1998970
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the systemic toxicity and pharmacokinetics of the immunoconjugate anti-B4-blocked ricin in non-human primates. Delivered by multiple bolus injections and by continuous infusion.
Shah SA; Lambert JM; Goldmacher VS; Esber HJ; Levin JL; Chungi V; Zutshi A; Braman GM; Ariniello PD; Taylor JA
Int J Immunopharmacol; 1993 Aug; 15(6):723-36. PubMed ID: 7691767
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of intrathecal transferrin-ricin a chain immunotoxin.
Candiani C; Tommasi M; Fracasso G; Lorenzetti I; Adami A; Benoni G; Tridente G; Colombatti M
Life Sci; 2001 Jun; 69(3):335-46. PubMed ID: 11441924
[TBL] [Abstract][Full Text] [Related]
11. Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies.
Vallera DA; Burns LJ; Frankel AE; Sicheneder AR; Gunther R; Gajl-Peczalska K; Pennell CA; Kersey JH
J Immunol Methods; 1996 Oct; 197(1-2):69-83. PubMed ID: 8890895
[TBL] [Abstract][Full Text] [Related]
12. A phase-I study of an anti-CD25 ricin A-chain immunotoxin (RFT5-SMPT-dgA) in patients with refractory Hodgkin's lymphoma.
Engert A; Diehl V; Schnell R; Radszuhn A; Hatwig MT; Drillich S; Schön G; Bohlen H; Tesch H; Hansmann ML; Barth S; Schindler J; Ghetie V; Uhr J; Vitetta E
Blood; 1997 Jan; 89(2):403-10. PubMed ID: 9002941
[TBL] [Abstract][Full Text] [Related]
13. Clinical trials with an anti-CD25 ricin A-chain experimental and immunotoxin (RFT5-SMPT-dgA) in Hodgkin's lymphoma.
Schnell R; Vitetta E; Schindler J; Barth S; Winkler U; Borchmann P; Hansmann ML; Diehl V; Ghetie V; Engert A
Leuk Lymphoma; 1998 Aug; 30(5-6):525-37. PubMed ID: 9711915
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.
Masui H; Kamrath H; Apell G; Houston LL; Mendelsohn J
Cancer Res; 1989 Jul; 49(13):3482-8. PubMed ID: 2786451
[TBL] [Abstract][Full Text] [Related]
15. Intra-thecal treatment of leptomeningeal lymphoma with immunotoxin.
Urch CE; George AJ; Stevenson GT; Bolognesi A; Stirpe F; Weller R; Glennie MJ
Int J Cancer; 1991 Apr; 47(6):909-15. PubMed ID: 2010234
[TBL] [Abstract][Full Text] [Related]
16. Stability and cytotoxicity of Fab-ricin A immunotoxins prepared with water soluble long chain heterobifunctional crosslinking agents.
Woo BH; Lee JT; Park MO; Lee KR; Han JW; Park ES; Yoo SD; Lee KC
Arch Pharm Res; 1999 Oct; 22(5):459-63. PubMed ID: 10549572
[TBL] [Abstract][Full Text] [Related]
17. Uptake of native and deglycosylated ricin A-chain immunotoxins by mouse liver parenchymal and non-parenchymal cells in vitro and in vivo.
Blakey DC; Skilleter DN; Price RJ; Thorpe PE
Biochim Biophys Acta; 1988 Feb; 968(2):172-8. PubMed ID: 3257705
[TBL] [Abstract][Full Text] [Related]
18. A combination of anti-CD3 and anti-CD7 ricin A-immunotoxins for the in vivo treatment of acute graft versus host disease.
van Oosterhout YV; van Emst L; Schattenberg AV; Tax WJ; Ruiter DJ; Spits H; Nagengast FM; Masereeuw R; Evers S; de Witte T; Preijers FW
Blood; 2000 Jun; 95(12):3693-701. PubMed ID: 10845899
[TBL] [Abstract][Full Text] [Related]
19. Production of anti-CD3 and anti-CD7 ricin A-immunotoxins for a clinical pilot study.
van Oosterhout YV; van Emst JL; Bakker HH; Preijers FW; Schattenberg AV; Ruiter DJ; Evers S; Koopman JP; de Witte T
Int J Pharm; 2001 Jun; 221(1-2):175-86. PubMed ID: 11397579
[TBL] [Abstract][Full Text] [Related]
20. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]